Teva Pharmaceutical Industries (TEVA) Q2 2025 earnings summary

Executive summary

• Achieved 10th consecutive quarter of revenue growth, with Q2 2025 revenues at $4.2 billion, up 1% year-over-year, driven by innovative products AUSTEDO, UZEDY, and AJOVY.

• Innovative portfolio revenues grew significantly, with AUSTEDO, UZEDY, and AJOVY showing strong year-over-year gains.

• Transformation programs and cost optimization are on track, targeting $700 million in net savings by 2027, with $140–$150 million annual run-rate savings in 2025.

• Operating income reached $455 million, reversing a prior-year loss; net income attributable to shareholders was $282 million.

• Guidance for 2025 reaffirmed, with raised outlook for key innovative products and a clear path to 30% operating margin by 2027.

Financial highlights

• Q2 2025 revenues: $4.2 billion (up 1% YoY, excluding Japan divestiture); adjusted EBITDA: $1.2 billion (up 17% YoY); non-GAAP EPS: $0.66 (up 10% YoY); free cash flow: $476 million (up 47% YoY).

• Gross profit margin improved to 50.3% (GAAP) and 54.6% (non-GAAP), both up year-over-year.

• Operating income (GAAP) reached $455 million; non-GAAP operating income was $1.13 billion (27.1% margin).

• Net income attributable to shareholders was $282 million (GAAP); non-GAAP net income was $769 million.

• Gross debt reduced to $17.2 billion; net debt at $15.1 billion; net debt/EBITDA at 3.09x.

Outlook and guidance

• 2025 revenue guidance: $16.8–$17.2 billion; non-GAAP operating income: $4.3–$4.6 billion; adjusted EBITDA: $4.7–$5.0 billion; non-GAAP EPS: $2.50–$2.65.

• Raised 2025 revenue outlook for AUSTEDO ($2.0–$2.05B), AJOVY ($630–$640M), and UZEDY ($190–$200M).

• Free cash flow guidance: $1.6–$1.9 billion; annual non-GAAP tax rate expected at 15–18%.

• On track for 2027 targets: 30% operating margin, 2x net debt/EBITDA, and investment-grade rating.

• Management expects sufficient liquidity and compliance with financial covenants for the next year.